Virus-like liposomes targeting CD169+ dendritic cells as a novel carrier for cancer immunotherapy
Abstract
Cancer is accounting for 26% of all deaths worldwide. While the introduction of checkpoint inhibitors has dramatically changed the outlook of some cancers, only a fraction of all cancer patients benefits from these therapies, mainly due to a failed immune cell activation directed to the tumor.1) Classical vaccination approaches have so far failed to boost sufficiently strong immune responses to combat cancer, and therefore there is an urgent need for new strategies to be developed to induce effective anti-tumor immune responses.2)
In this study, we propose the development of virus-like liposomes as a novel dendritic cell-targeted vaccination strategy in which we will use ligands of CD169 molecules expressed on antigen presenting cells, immune-activating viral-mimic molecules as adjuvant, and encapsulated tumor antigens.3)4) Using combination of in vitro assays and in vivo models, this study will investigate the efficacy of virus-like liposomes as novel nano-vaccine carriers that targets CD169+ antigen presenting cells for cross-presentation and tumor-specific T cell activation.
Benefit for the community
The prognosis of cancer patients, especially those diagnosed late in disease progression, is extremely poor. Therefore, new types and better therapies are urgently needed. Our aim is to develop a vaccination strategy that can be combined with other immunotherapies to prolong survival and to contribute to a better quality of life for cancer patients.
Visit the supervisors lab
T Cell-Inflamed versus Non-T Cell-Inflamed Tumors: A Conceptual Framework for Cancer Immunotherapy Drug Development and Combination Therapy Selection
Cancer Immunol. Res. 6, 990-1000
PubMed |
Purification and properties of sialoadhesin, a sialic acid-binding receptor of murine tissue macrophages
EMBO J. 10, 1661-1669
PubMed |
Functional CD169 on Macrophages Mediates Interaction with Dendritic Cells for CD8+ T Cell Cross-Priming
Cell Rep. 22, 1484-1495
PubMed |
CD169 Defines Activated CD14(+) Monocytes With Enhanced CD8(+) T Cell Activation Capacity
Front. Immunol. 12, 697840
PubMed |
Liposome induction of CD8(+) T cell responses depends on CD169(+) macrophages and Batf3-dependent dendritic cells and is enhanced by GM3 inclusion
J. Controlled Release 331, 309-320
PubMed |
Liposomal Nanovaccine Containing α-Galactosylceramide and Ganglioside GM3 Stimulates Robust CD8(+) T Cell Responses via CD169(+) Macrophages and cDC1
Vaccines (Basel) 9, 56
PubMed |
Incorporation of Toll-Like Receptor Ligands and Inflammasome Stimuli in GM3 Liposomes to Induce Dendritic Cell Maturation and T Cell Responses
Front. Immunol. 13, 842241
PubMed |